glp 1 medication shortage FDA's compounded GLP-1 limits will have ripple effects throughout the retail industry Telehealth company Ro rolls out

muciniphila supplementation demonstrates therapeutic efficacy in improving insulin sensitivity in obese and type 2 diabetic patients, and shows potential in mitigating Parkinson's disease pathology by regulating -synuclein oligomerization

Here's what seniors and their providers need to know...

Could they also add years to your life?

Notably, AA reduces septal DAT function pointing to AA as a novel regulator of central DA homeostasis

Transform your digestion and overall wellbeing today

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction